SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance

Clara Di Germanio1 | Graham Simmons1,2 | Kathleen Kelly3 | Rachel Martinelli1 | Orsolya Darst1 | Mahzad Azimpouran1 | Mars Stone1,2 | Kelsey Hazegh3 | Eduard Grebe1,2 | Shuting Zhang4,5,6 | Peijun Ma4,5,6 | Marek Orzechowski4 | James E. Gomez4 | Jonathan Livny4 | Deborah T. Hung4,5,6 | Ralph Vassallo7 | Michael P. Busch1,2 | Larry J. Dumont3,8

1Vitalant Research Institute, San Francisco, California, USA
2Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
3Vitalant Research Institute, Denver, Colorado, USA
4Infectious Disease and Microbiome Program, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA
5Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, USA
6Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA
7Vitalant, Scottsdale, Arizona, USA
8University of Colorado School of Medicine, Aurora, Colorado, USA

Abstract

Background: Antibody response duration following severe acute respiratory syndrome coronavirus 2 infection tends to be variable and depends on severity of disease and method of detection.

Study design and methods: COVID-19 convalescent plasma from 18 donors was collected longitudinally for a maximum of 63–129 days following resolution of symptoms. All the samples were initially screened by the Ortho total Ig test to confirm positivity and subsequently tested with seven additional direct sandwich or indirect binding assays (Ortho, Roche, Abbott, Broad Institute) directed against a variety of antigen targets (S1, receptor binding domain, and nucleocapsid [NC]), along with two neutralization assays (Broad Institute live virus PRNT and Vitalant Research Institute [VRI] Pseudovirus reporter viral particle neutralization [RVPN]).

Results: The direct detection assays (Ortho total Ig total and Roche total Ig) showed increasing levels of antibodies over the time period, in contrast to the indirect IgG assays that showed a decline. Neutralization assays also demonstrated declining responses; the VRI RVPN pseudovirus had a greater rate of decline than the Broad PRNT live virus assay.

Clara Di Germanio and Graham Simmons contributed equally to this study.

Abbreviations: ACE2, angiotensin-converting enzyme 2; Ag, antigen; AU, Arbitrary Units; CCP, COVID-19 convalescent plasma; CMIA, chemiluminescent microparticle immunoassay; CoV2G, Ortho VITROS Anti-SARS-CoV-2 IgG; CoV2T, Ortho VITROS Anti-SARS-CoV-2 Total; COVID-19, Coronavirus disease 2019; CTS, creative testing solutions; DIN, donation identification number; EBLUP, empirical best linear unbiased predictor; ELISA, enzyme-linked immunosorbent assay; EUA, emergency use authorization; FDA, United States Food and Drug Administration; ID50, Half-maximal inhibitory dilution; Ig, immunoglobulin; IgA, Immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; MASS-BD, US National Blood Donor Serosurveillance Study; NC, nucleocapsid protein; NT50, Half-maximal neutralization titer; PRNT, plaque reduction neutralization test; RBD, receptor binding domain of S1; RVPN, reporter viral particle neutralization; RLU, relative light units; S1, spike subunit; S/CO, signal-to-cutoff ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TMPRSS2, Transmembrane Serine Protease 2; VRI, Vitalant Research Institute; VSV, vesicular stomatitis virus; VISP, vaccine induced seropositivity.
1 | INTRODUCTION

In the past several months, research on Coronavirus Disease 2019 (COVID-19) immune response has confirmed that the majority of infected individuals mount antibody responses to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the disease.\(^1\) Increasing evidence suggests that more rapid and potent humoral responses correlate with the severity of disease,\(^2\, 3\) likely due to greater and longer exposure to the viral antigen. The antibody response to acute viral infections typically declines from peak titers following recovery from acute infection. Conflicting reports have described the rapidity of antibody decline following SARS-CoV-2 infection, with some studies reporting a rapid decay of anti-SARS-CoV-2 antibodies,\(^3\, 4, 5, 6\) while others have described stable short-term responses\(^7\) or even a sustained response, up to 8 months after infection.\(^8\) In keeping with the strength of the initial humoral response correlating with severity of disease, many of the studies demonstrating rapid waning of anti-viral responses have been performed in asymptomatic individuals or patients with mild symptoms. Indeed, in a direct comparison, antibodies decayed more rapidly in mild cases compared to severe infection.\(^9\) This finding is in line with previous studies for other coronaviruses.\(^10\) However, there is also evidence that some of the variability seen in these studies is due to the serological assays deployed.\(^8\) Different antibody isotypes, antibodies targeting different antigens and epitopes, and different assay formats (indirect, direct) are likely to wane with differing kinetics, making some immunoassay approaches more effective than others. The most common commercially available assays target either the spike subunit (S1) that mediates viral entry, the receptor binding domain (RBD) of S1 which binds to its human cellular receptor angiotensin-converting enzyme 2 (ACE2), or the nucleocapsid (NC) protein that encapsulates the viral genome.\(^11\)

Using 18 repeat donors of COVID-19 convalescent plasma (CCP), we studied the kinetics of antibody evolution and decline up to 129 days after resolution of COVID-19 symptoms. Eight antibody binding assays on different platforms and targeting different antibody isotypes and viral antigens were investigated, as well as two assays of viral neutralization (Table 1). This allowed in-depth comparison between assays and antigen targets in order to identify assays that may be suited for different purposes such as serodiagnosis of recently acquired infection, serosurveillance, correlates of immune protection, or potency of CCP. Assays that effectively detect and quantify long-lasting serological responses are important tools for making accurate seroprevalence estimates of previous infection to track incidence over time. Alternately, immunoassays that demonstrate a rapidly waning response may be useful for performing recency studies, identifying hotspots of infection and predicting subsequent protective immunity at the individual and population level (i.e., herd immunity). High-throughput assays waning in parallel with neutralizing antibody response may also be particularly valuable in the characterization of CCP neutralizing antibody content.

2 | METHODS

2.1 | COVID-19 convalescent plasma

CCPs were collected in the Vitalant system following FDA Guidance for donor eligibility\(^12\) as previously described.\(^13\) These criteria evolved throughout the study period due to testing availability and evolution of the pandemic in the United States. Evidence of COVID-19 was required in the form of a documented positive SARS-CoV-2 molecular or serologic test, and complete resolution of symptoms initially at least 14 days prior to donation (with a negative molecular test if <28 days), but...
then a minimum of 28 days was implemented. All CCP donors were also required to meet traditional allogeneic blood donor criteria. At the time of plasma collection, donors consented to use of de-identified donor information and test results for research purposes. Medical Director approval was obtained for CCP collection every 7 days for interested donors. Between April 8 and October 20, 2020, approximately 50,000 units were released from 7976 unique donors. All CCPs were tested for SARS-CoV-2 total Ig antibody using the Ortho VITROS CoV2T assay at our central testing laboratory (Creative Testing Solutions [CTS], Scottsdale, AZ). CCP qualification requires the signal-to-cutoff ratio S/CO of this test to be at least 1.0 according to the manufacturer’s instructions defining a reactive result. These test results were not used to select “high titer” CCP units as defined in the FDA CCP EUA issued in September 2020. At least 2 collections were conducted for 2507 donors in this period. Of these, 275 had greater than four donations and an interval from the first to last donation of over 60 days. We selected a convenience subset of 19 unique donors for evaluation of the persistence of SARS-CoV-2 Ab with date range from first to last donation 47–99 days (resolution of symptoms to last donation 63–129 days) and 4–12 total donations. This sample was selected to cover the range of initial S/CO values observed at the first donation. One donor was subsequently removed from the analysis set for cause because only two retained serum samples were retrievable and these were negative for neutralizing antibody. For the present analysis, donor COVID-19 symptom and SARS-CoV-2 testing histories were reviewed. The time course of longitudinal donations was determined based on the date of resolution of all disease symptoms.

### 2.2 Antibody measurement

#### 2.2.1 Sample handling

Ortho VITROS Anti-SARS-CoV-2 total testing performed at CTS was on serum samples obtained at the time of collection, transported overnight to CTS from the collection location with standard donation infectious disease screening samples, and processed within 18 h (i.e., no freeze–thaw). Serum and plasma for other assays were prepared at the time of collection, frozen at ≤−18°C within 2 h, transported to a central repository on dry ice and stored at ≤−65°C. Aliquots were prepared after one thaw followed by freezing and storage at ≤−65°C. Frozen samples were transported to testing laboratories on dry ice. Testing laboratories thawed samples and processed samples together in one or two batches (i.e., two freeze–thaw cycles). The Broad assays were performed on samples that underwent one additional freeze–thaw cycle.

### 2.3 Direct detection

#### 2.3.1 Ortho VITROS Anti-SARS-CoV-2 total

The Ortho VITROS Anti-SARS-CoV-2 total (CoV2T, Ortho-Clinical Diagnostics, Inc., Rochester, NY) was used at CTS to detect total (IgG, IgM, and IgA) antibodies in plasma.

| MFR | Assay | Antigen | Format | EUA status | Testing lab |
|-----|-------|---------|--------|------------|-------------|
| Direct detection Ab binding | Ortho | Vitos Cov2T | S1 | Total Ig antigen sandwich | Yes | CTS |
| | Roche | Elecsys® Anti-SARS-CoV-2 | NC | Total Ig antigen sandwich ECLIA | Yes | CTS |
| Indirect detection Ab binding | Abbott | SARS-CoV-2 IgG Architect | NC | IgG CMIA | Yes | Abbott |
| | Abbott | SARS-CoV-2 IgG II Quant Architect | S1-RBD | IgG CMIA | No | Abbott |
| | Abbott | SARS-CoV-2 IgG II Quant Alinity | S1-RBD | IgG CMIA | No | Abbott |
| | Ortho | Vitos CoV2G | S1 | IgG | Yes | Ortho |
| | BROAD | ELISA | S1-RBD | IgG | No | Broad Institute |
| | BROAD | ELISA | NC | IgG | No | Broad Institute |

**Neutralization**

| MFR | Assay | Antigen | Format | EUA status | Testing lab |
|-----|-------|---------|--------|------------|-------------|
| VRI-SF | Pseudotype VSV | Spike | HEK293T/ACE2/TMPRSS2 | No | VRI-SF |
| BROAD | Live virus | Live virus | Vero-TMPRSS2 | No | Broad Institute |

**Table 1 SARS-CoV-2 antibody binding and neutralization assays**

**Abbreviations:** CTS, Creative Testing Solutions; NC, nucleocapsid; RVPN, reporter viral particle neutralization; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VRI, Vitalant Research Institute.
against the spike S1 protein, as previously described. Briefly, serum samples are quickly vortexed, loaded on Ortho VITROS XT-7200 or 3600 instruments (Ortho Clinical Diagnostics, Raritan, NJ) and programmed for the CoV2T test following the manufacturer’s instructions. The S1 antigens coated on the assay wells bind S1 antibodies from human serum which, in turn, bind to a secondary HRP-labeled S1 antigen in the conjugate reagent forming a sandwich. The addition of signal reagent containing luminol generates a chemiluminescence reaction that is measured by the system and quantified as the ratio of the signal relative to the cut-off value generated during calibration. An S/CO ≥1 is considered positive.

2.3.2 | Roche cobas Anti-SARS-CoV-2

The Elecsys Anti-SARS-CoV-2 immunoassay (Roche NC) was run at CTS on the cobas e441 analyzer (Roche Diagnostics, Indianapolis, IN) to detect antibodies against the SARS-CoV-2 nucleocapsid protein. Plasma samples are initially incubated with biotinylated and ruthenium-labeled SARS-CoV-2 recombinant nucleocapsid antigens and any antibody present in the solution is sandwiched between the two. Subsequently, streptavidin-coated microparticles are added to the mixture to bind the biotin. The magnetic particles drive the complexes to the electrode, where a chemiluminescent signal is emitted and measured as the ratio between the signal and the cut-off obtained during calibration. Similar to the VITROS, a S/CO ≥1 is considered positive.

2.4 | Indirect detection

2.4.1 | Ortho VITROS Anti-SARS-CoV-2 IgG

Levels of IgG antibodies were measured in plasma by the Ortho VITROS Anti-SARS-CoV-2 IgG (CoV2G, Ortho-Clinical Diagnostics, Inc., Rochester, NY) at Ortho Diagnostics using a quantitative RUA assay. Similar to the VITROS CoV2T, in the first step the antibodies present in the specimen bind to the S1 spike on the testing wells. However, in the following stage, HRP-conjugated murine monoclonal anti-human IgG antibodies are added, targeting the antibody portion of the complex. When the luminogenic substrate is added, chemiluminescence is then measured and quantified as a S/CO, with values ≥1 considered positive.

2.4.2 | Abbott architect SARS-CoV-2 IgG

A qualitative SARS-CoV-2 IgG assay targeting IgG against nucleocapsid protein was performed by Abbott (Architect NC IgG, Abbott Diagnostics, Abbott Park, IL) on the Architect platform using chemiluminescent microparticle immunoassay (CMIA) technology. An additional quantitative assay, SARS-CoV-2 IgG II Quant (not available in the U.S.) was performed on the Architect and Alinity platforms to detect and measure IgG against the RBD of the S1 protein of the virus. Plasma samples are incubated with SARS-CoV-2 antigen coated on magnetic microparticles which bind IgG antibodies against SARS-CoV-2. These complexes are then incubated with anti-human IgG acridinium-labeled conjugate, which result in a chemiluminescence reaction upon addition of trigger solution. Results are reported as an index value (S/C) comparing RLU (relative light units) from the samples and the calibrator for the IgG assay and as Arbitrary Units/ml (AU/ml) comparing RLU from the sample relative to the RLUs obtained from a 6-point calibration curve for the IgG II assay. Values ≥1.40 S/C on the IgG assay and ≥50 AU/ml on the IgG II assay are considered positive.

2.5 | Neutralization assays

2.5.1 | Broad institute live virus neutralization

Live-virus SARS-CoV-2 antibody neutralization was performed at Broad Institute on a high throughput platform
Vero E6-TMPRSS2 were seeded at 10,000 cells per well the day prior to infection in a CellCarrier-384 ultra-microplate (Perkin Elmer). Patient serum samples were tested at a starting dilution of 1:40 and were serially diluted 2-fold up to eight dilution spots. Serially diluted patient sera were mixed separately with diluted SARS-CoV-2 live virus (D614) and incubated at 37°C with 5% CO₂ for 1 h; after which the sera-virus complexes were added to the Vero E6-TMPRSS2 cells and incubated at 37°C with 5% CO₂ for 48 h. Cells were then fixed using 4% paraformaldehyde in PBS for 2 h at room temperature, washed, and incubated with diluted anti-SARS-CoV/SARS-CoV-2 nucleoprotein mouse antibody (Sino Biological) for 1.5 h at room temperature. They were subsequently incubated with Alexa488-conjugated goat anti-mouse (Jackson ImmunoResearch Labs) for 45 min at room temperature, followed by nuclear staining with Hoechst 33342 (Thermo Fisher Scientific). Fluorescence imaging was performed using the Opera Phenix™ High Content Screening System (Perkin Elmer). Half-maximal inhibitory dilutions (ID50) were determined using a four-parameter, nonlinear curve fitting algorithm. Samples whose curves lay above 0.5 for all the data points were considered non-neutralizing, with ID₅₀ = 20, while samples whose curves fell below 0.5 were considered highly neutralizing and assigned an ID₅₀ = 10,240.

2.5.2 Vitalant Research Institute pseudovirus neutralization

Serum samples were tested at Vitalant Research Institute (VRI) for SARS-CoV-2 reporter viral particle neutralization (RVPN) as previously described using the Wuhan-Hu-1 spike sequence (GenBank: MN908947.3) modified by addition of the D614G mutation and removal of 21 C-terminal amino acids demonstrated to enhance incorporation into viral particles. Recombinant vesicular stomatitis virus (VSV) containing firefly luciferase gene (Kerafast, Boston, MA) and incorporating SARS-CoV-2 spike were added to heat inactivated samples diluted four-fold, together with positive, negative and no-serum controls. The resulting mix was incubated and then added to 96-well plates containing ACE2 and TMPRSS2 expressing HEK293T cells. Eighteen to 24 h later, luciferase activity was measured on a chemiluminescence reader (BMG CLARIOStar, BMG LABTECH Inc., Cary, NC) after lysing the cells. Neutralization titers were calculated as a percentage of no-serum control and the NT₅₀ was estimated from the dilution curve using Prism8 (GraphPad Software, San Diego, CA). Titers below 40 were considered non-neutralizing.

2.6 Statistical analysis

Primary assay outcomes from VRI RVPN, BROAD PRNT, BROAD NC, BROAD RBD, Ortho CoV2T, Abbott Alinity S IgG, and Abbott Architect S IgG were logarithmically (base 10) transformed to meet the regression model assumption requirements. The Roche NC, Ortho CoV2G, and Abbott Architect NC IgG outcome signals remained in the reported scale. These data were then standardized using a z-transformation by assay:

\[
y'_{ij} = \frac{y_{ij} - \mu_j}{\sigma_j}
\]

Standardized outcomes were fit to a mixed linear model of z-signal regressed on the time from resolution of signs and symptoms as reported by the donor. Random variables of intercept and slope were nested within assay with repeated measures for serum sample (DIN) and donor as subject. Thus, the overall slope and intercept solution for each assay were adjusted by individual donor random effects. Plots of the regression solution for each assay were constructed showing the overall estimated z-signal over time with the empirical best linear unbiased predictor (EBLUP) for each donor. Pearson conditional residuals were examined to evaluate the final model assumptions and fit; and were found to support the key assumptions of independence and normality (Proc Stdzize
Hypotheses tests were conducted using the model at $p > .05$ as significant. $p$-values were not adjusted for multiple comparisons.

**FIGURE 2** Antibody stability over time post resolution of COVID-19 symptoms—assay signals as reported. See Table 1 for assay descriptions. (A) Indirect detection method assays using anti-IgG secondary antibodies. (B) Left panels—direct detection method assays using SARS-CoV-2 antigen detection. Right panels—neutralizing antibody assays. COVID-19, Coronavirus Disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 [Color figure can be viewed at wileyonlinelibrary.com]
To determine if the sample selected was representative of the total number of donors with multiple donations over the period, we evaluated the Ortho VITROS CoV2T signal over time from first donation for the 275 donors with >60 days maximum observation period at >4 donations. These data were evaluated by regression as described earlier and compared to the subset of 18 subjects chosen for this study.

3 | RESULTS

Figure 1 shows the Ortho CoV2T S/CO results for 275 unique donors with at least 4 donations spanning a minimum of 60 days during the observation period. The 18 unique donors selected for additional antibody testing in this study are highlighted, and the regression solutions for all donors and the selected donor subset are shown. The 18 (14 male/4 female) evaluable donors all had symptomatic COVID-19 (median 17 days of symptoms; range 3–22). Seventeen were confirmed by positive swab testing, the other by antibody testing. The donors’ median age was 57 (range 22–73). Evaluable serum samples were available for testing through a maximum of 63–129 days following the resolution of COVID-19 signs and symptoms.

The 18 donors had 873 evaluable observations. The reported, non-transformed assay signals by donor for each assay are shown in Figure 2. Large differences are noted between donor antibody assay signals in each assay. Figure 3 displays the regression result for the standardized outcomes for each assay showing the individual solutions for each donor and the overall average. The standardized slopes for each assay are shown in Table 2 and Figure 4. Total antibody levels determined by direct-detection, sandwich methods (Ortho CoV2T, Roche NC) increased over the course of observation. The rate of change over time (slopes) were not different between
Ortho CoV2T and Roche NC, \( p = .66 \). The six indirect, IgG assays showed declining levels. The declines in the standardized assay outcome (slope) for the indirect binding IgG assays comprised of different S1, RBD, and NC antigens were not significantly different, \( p = .70 \). The BROAD PRNT assay values declined throughout the observation period at a rate not different than the indirect binding assays (\( p = .75 \)). The VRI RVPN pseudovirus test demonstrated consistent decline (\( -0.0230 \pm 0.0018 \) 95% confidence interval: \( -0.0266 \) to \( -0.0194 \), \( p < .0001 \)), and was significantly greater than the BROAD PRNT waning, \( p < .0001 \).

### TABLE 2

| Assay                  | Slope       | 95% CI          | \( p \) |
|------------------------|-------------|-----------------|--------|
| Ortho VITROS CoV2T     | 0.0066 ± 0.0017 | 0.0032 to 0.0099 | <.0001 |
| Roche NC               | 0.0052 ± 0.0017 | 0.0018 to 0.0086 | .003   |
| Ortho VITROS CoV2G     | -0.0059 ± 0.0017 | -0.0093 to -0.0026 | <.0001 |
| BROAD PRNT ID \(_{50}\) | -0.0065 ± 0.0018 | -0.0101 to -0.0030 | <.0001 |
| BROAD RBD ELISA        | -0.0066 ± 0.0018 | -0.0102 to -0.0031 | <.0001 |
| BROAD NC ELISA         | -0.0072 ± 0.0018 | -0.0108 to -0.0037 | <.0001 |
| Abbott Architect-S IgG II Quant | -0.0087 ± 0.0017 | -0.0120 to -0.0053 | <.0001 |
| Abbott Alinity-S IgG II Quant | -0.0088 ± 0.0017 | -0.0121 to -0.0054 | <.0001 |
| Abbott Architect-NC IgG | -0.0093 ± 0.0017 | -0.0126 to -0.0059 | <.0001 |
| VRI RVPN NT \(_{50}\)  | -0.0230 ± 0.0018 | -0.0266 to -0.0194 | <.0001 |

Abbreviations: NC, nucleocapsid; RVPN, reporter viral particle neutralization; VRI, Vitalant Research Institute.

### 4 DISCUSSION

This study accessed longitudinal samples from CCP donors with intervals between resolution of disease symptoms and last donation of 63–129 days and 4–12 total donations per donor to evaluate and compare the persistence of antibody reactivity of 10 SARS-CoV-2 antibody assays. These assays included six commercial assays with different antigen targets (S1, RBD, NC) and detection formats (direct detection by antigen labeled conjugate; indirect detection using anti-human IgG labeled conjugate), S1 RBD and NC-based assays developed at the Broad Institute, and live and pseudovirus-based neutralization assays. These assays represent the diversity of tests employed for serodiagnosis, serosurveillance, and characterization of levels of binding and neutralizing activity for assessment of efficacy of passive immunotherapies (CCP, monoclonal antibodies, hyperimmune IgG preparations), estimation of vaccine efficacy, and durability of humoral immunity following infection or vaccination that may correlate with protection from reinfections following convalescence or vaccination.

We observed that SARS-CoV-2 antibody assays provided different longitudinal profiles for antibody reactivity over 18 weeks post resolution of COVID-19 symptoms. The commercial direct detection (antigen sandwich format) assays show steady to increasing signals over time while indirect detection IgG assays show declining signals over time. The neutralizing Ab assays had declining responses over time although the change in the BROAD PRNT live virus assay over the 129-day period was not different than the indirect-detection binding assays, whereas the VRI RVPN pseudovirus assay was the most sensitive to the change in viral neutralization over this period.
Not considered in the present study is the effect of changing antibody avidity, a measure of the strength of antibody–antigen association. Lou et al. have observed increasing anti-SARS-CoV-2 avidity over the course of infection and recovery. The increase in assay signal observed in the present study with the direct-detection methods could be a result of increasing avidity over time even in the face of decreasing anti-SARS-CoV-2 IgG as observed in the indirect assays. If true, even with the increasing avidity over time, the waning IgG levels strongly correlated with the waning neutralizing antibody assays. Extension of this work to explore longer follow-up periods beyond 130 days post signs and symptoms as well as the assessment of antibody avidity would add to understanding clinical protective effects as well as indications of reinfections.

These findings complement and extend reports from other studies of antibody persistence following infection. The majority of studies have focused on durability of antibodies detected by commercial or lab-developed indirect IgG assays and neutralizing assays, with most studies documenting waning of antibodies following peak reactivity approximately 1 month post-seroconversion. Multiple studies have also correlated the waning of binding assay reactivities, and particularly IgG assays with S1, RBD and NC antigens, relative to waning neutralizing antibodies to identify high throughput and low cost assays that could serve as proxies for live virus PRNT or pseudovirus RVPN assays. These analyses have demonstrated variable correlations and predictive values of S1, RBD and NC-based immunoassays with waning neutralizing activity. The first high throughput test designated by the US FDA for use in labeling CCP with high- or low-titer antibody content was the Ortho CoV2G IgG assay. Notably, the Abbott Architect SARS-CoV-2 IgG and Ortho Vitros Anti-SARS-CoV-2 IgG assays used in the present study, were also among those found acceptable for this purpose.

For serosurveillance studies, which have been widely implemented regionally, nationally and internationally to monitor SARS-CoV-2 transmission dynamics using serial cross-sectional sample sets from populations including blood donors, the preferred assay(s) would have sustained antibody reactivity over at least 6 months and optimally longer to accurately track cumulative incidence. If assays that are susceptible to rapid waning of seroreactivity are employed in serosurveillance studies, significant proportions of previously infected persons could have seroreverted in downstream waves of sample collection and testing. Such waning can be addressed by statistical adjustments in analyses, based on patterns of waning using CCP sample sets of findings from serial cross-sectional results, as recently done in a large study from Brazil based on the Abbott NC IgG assay included in the present study. But these adjustments require parallel data on waning profiles, are complex, and have led to debate over the validity and generalizability of serosurveillance findings in studies employing assays that demonstrate antibody waning. In contrast, the direct antigen sandwich assays that we evaluated, which included the S1-based total Ig assay from Ortho and NC-based total Ig assay from Roche, are optimal for application in serosurveillance studies given the stability and even increasing levels of reactivity observed over time, presumably due to continued maturation of antibody affinity and/or avidity resulting in increasing signal intensity in these assays. The pattern of persistence and even increasing reactivity of these assays which we observed with serial convalescent plasma donations has also been observed in analyses of serial donations by regular blood donors screened with these assays and by another antigen sandwich configuration assay by Wantai. Moreover, by combining S- and NC-based direct antigen sandwich assays into algorithms for confirmation of seroreactivity it is possible to minimize the potential contribution of false positive results to estimates of cumulative incidence of natural infections over time and across regional and demographic subgroups. This algorithm has been adopted in the US REDS-IV-P RESPONSE and National Blood Donor Serosurveillance Studies (MASS-BD).

As SARS-CoV-2 vaccines are being rapidly approved and implemented to mitigate the pandemic, there will be a need for combinations of S- and NC-based assays or multiplexed S/RBD/NC assays to detect and discriminate antibodies induced by natural infection from vaccine induced seropositivity (VISP). Assays/algorithms will also be needed to monitor vaccine penetrance and persistence of VISP, as well as to detect breakthrough infections in vaccinated persons following ongoing exposures to SARS-CoV-2. The algorithm adopted for the US National Blood Donor Serosurveillance Study (MASS-BD) that employs the Ortho CoV2T total Ig assay followed by the Roche NC total Ig assay on all S1 antibody reactive samples should allow for simultaneous and accurate detection of VISP and natural infection induced seropositivity, and has the potential to surveil for vaccine breakthrough infections in longitudinal databases of repeat blood donors who were determined to be previously vaccinated.

Measuring antibody levels over time within populations, including CCP and routine blood donors, may also provide valuable data on risk of reinfections. Reinfections will likely induce anamnestic boosting of antibody reactivity to both S and NC antigens. Such boosting will be particularly apparent with assays that are prone to waning, such as the Abbott NC and RBD IgG assays and pseudovirus RVPN assay. Hence, different assays and different
combinations of SARS-CoV-2 antibody assays will be needed to address the multiple important questions that are arising as the pandemic and mitigation strategies evolve. There is evolving appreciation of different applications or use cases for serological testing that will require different assays/algorithms for the next phase of COVID-19 pandemic response. The addition of antibody avidity determination in these assessments may additionally contribute to the understanding of antibody clinical protective effects as well as indicators of reinfections.

ACKNOWLEDGMENTS
Abbott Diagnostics & Ortho-Clinical Diagnostics kindly provided reagents and testing services for their assay platforms. Thanks and acknowledgements also are extended to the extended teams at Vitalant Research Institute and the Broad Institute that managed sample procurement, preparation, testing, and data verification.

CONFLICT OF INTEREST
The authors have disclosed no conflicts of interest.

REFERENCES
1. Long Q-X, Liu B-Z, Deng H-J, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8.
2. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2020;147:545–57. https://doi.org/10.1016/j.jaci.2020.03.051
3. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–4.
4. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hauser MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383:1085–7.
5. Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR, et al. Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA. 2020;324:1781–2.
6. Perreault J, Tremblay T, Fournier M-J, Drouin M, Beaudoin-Bussières G, Prévost J, et al. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood. 2020;136:2588–91.
7. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227–30.
8. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. https://doi.org/10.1126/science.abf4063
9. Choe PG, Kang CK, Suh HJ, Jung J, Song KH, Bang JH, et al. Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection. Emerg Infect Dis. 2021;27(1):327–9. https://doi.org/10.3201/eid2701.203515
10. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101:791–7.
11. U.S. Food and Drug Administration. EUA authorized serology test performance. 2021;
12. U.S. Food and Drug Administration. Investigational COVID-19 convalescent plasma; guidance for industry. 2021.
13. Goodhue Meyer E, Simmons G, Grebe E, et al. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay. Transfusion. 2021;61:1160–70. https://doi.org/10.1111/trf.16321
14. Ortho Clinical Diagnostics. VITROS immunodiagnostic products anti-SARS-CoV-2 total reagent pack and VITROS immunodiagnostic products anti-SARS-CoV-2 total calibrator instructions for use. Version 3.0. Rochester, NY: Ortho Clinical Diagnostics, Inc.; 2020. https://www.orthoclinicaldiagnostics.com/>
15. Roche Diagnostics. Elecsys Anti-SARS-CoV-2 S. instructions for use version 1.0. Mannheim. https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2-s.html: Roche Diagnostics GmbH; 2020.
16. Ortho Clinical Diagnostics. VITROS immunodiagnostic products anti-SARS-CoV-2 IgG reagent pack and VITROS immunodiagnostic products anti-SARS-CoV-2 IgG calibrator instructions for use. Version 4.2. Rochester, New York. https://www.orthoclinicaldiagnostics.com/:
17. Architect SARS-CoV-2 IgG instructions for use. G90418R01. Abbott Laboratories Diagnostics DivisionAbbott Park, IL https://www.abbott.com/for-healthcare-professionals/diagnostics.html. 2020;
18. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181:271–280.e8.
19. Ng DL, Goldgof GM, Shy BR, Levine AG, Balercjak B, Bapat SP, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nat Commun. 2020;11:4698.
20. Luo YR, Chakraborty I, Yun C, Wu AHB, Lynch KL. Kinetics of SARS-CoV-2c entry dependent on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181:271–280.e8.
21. Luo YR, Yun C, Chakraborty I, Wu AHB, Lynch KL. A SARS-CoV-2 label-free surrogate virus neutralization test and a longitudinal study of antibody characteristics in COVID-19 patients. J Clin Microbiol. 2021. https://doi.org/10.1128/JCM.00193-21. Online ahead of print.
22. Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. medRxiv. 2021. https://doi.org/10.1101/2021.03.03.21251639
23. Salazar E, Kuchipudi SV, Christensen PA, Eager T, Yi X, Zhao P, et al. Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest. 2020;130:6728–38.

24. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, march 23-may 12, 2020. JAMA Intern Med. 2020;180:1576.

25. Rosenberg ES, Tesoriero JM, Rosenthal EM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann. Epidemiol. 2020;48:23–29.e4.

26. Shioda K, Lau MS, Kraay AN, et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. medRxiv. 2020. https://doi.org/10.1101/2020.11.13.20231266

27. Buss LF, Prete CA, Abrahim CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science. 2021;371:288–92.

28. Liu H, Wu NC, Yuan M, et al. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. Immunity. 2020;53:1272–1280.e5.

29. Benner SE, Patel EU, Laeyendecker O, Pekosz A, Littlefield K, Eby Y, et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J Infect Dis. 2020;222:1974–84.

30. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun. 2020;11:3436.

31. Babiker A, Marvil C, Waggoner JJ, Collins M, Piantadosi A. The importance and challenges of identifying SARS-CoV-2 reinfections. J. Clin. Microbiol. 2020;59(4):e02769–20. https://doi.org/10.1128/JCM.02769-20

32. Prete CA, Buss LF, Abraham CMM, et al. Reinfection by the SARS-CoV-2 P.1 variant in blood donors in Manaus, Brazil, medRxiv. 2021. https://doi.org/10.1101/2021.05.10.21256644

33. Gundlapalli AV, Salerno RM, Brooks JT, et al. SARS-CoV-2 serologic assay needs for the next phase of the US COVID-19 pandemic response. Open Forum Infect. Dis. 2021;8(1):ofaa555. https://doi.org/10.1093/ofid/ofaa555

34. Halteres SARS-CoV-2 use case tables Halteres Associates; https://halteresassociates.com/halteres-sars-cov-2-use-case-tables/.

35. Halteres-SARS-CoV-2-White-Paper-MUrdea https://halteresassociates.com/wp-content/uploads/2020/08/Halteres-SARS-CoV-2-White-Paper-MUrdea-20200812-v08.pdf.

How to cite this article: Di Germanio C, Simmons G, Kelly K, et al. SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. Transfusion. 2021;1–11. https://doi.org/10.1111/trf.16555